Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Steuber

Showing results (151-160 of 209) with videos related to

Pageof 21
Sort By:
European Urology|January 18, 2006
The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomyFelix K-H Chun, Alberto Briganti, Thierry Lebeau, et al.
European Urology|October 30, 2007
Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliterSascha A Ahyai, Markus Graefen, Thomas Steuber, et al.
European Urology Focus|July 21, 2017
Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical PracticeMariana Reza, Mattias Ohlsson, Reza Kaboteh, et al.
The Journal of Urology|February 13, 2014
A tertiary Gleason pattern in the prostatectomy specimen and its association with adverse outcome after radical prostatectomyMeike Adam, Amir Hannah, Lars Budäus, et al.
Urology|August 12, 2008
Assessment of biochemical recurrence rate in patients with pathologically confirmed insignificant prostate cancerUmberto Capitanio, Sasha Ahyai, Markus Graefen, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 17, 2008
Clinical significance of p53 alterations in surgically treated prostate cancersThorsten Schlomm, Liv Iwers, Patrick Kirstein, et al.
Current Oncology (Toronto, Ont.)|April 21, 2022
Concordance between Preoperative mpMRI and Pathological Stage and Its Influence on Nerve-Sparing Surgery in Patients with High-Risk Prostate CancerClara Humke, Benedikt Hoeh, Felix Preisser, et al.
Urologic Oncology|May 4, 2019
Prostate cancer prognosis in men with other malignancies prior to radical prostatectomyPeter Klippenstein, Thorsten Schlomm, Gunhild von Amsberg, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 4, 2010
The novel nomogram of Gleason sum upgrade: possible application for the eligible criteria of low dose rate brachytherapyLars Budäus, Markus Graefen, Georg Salomon, et al.
European Urology|August 17, 2015
Nerve-sparing Surgery Technique, Not the Preservation of the Neurovascular Bundles, Leads to Improved Long-term Continence Rates After Radical ProstatectomyUwe Michl, Pierre Tennstedt, Lena Feldmeier, et al.
Pageof 21

Showing results (151-160 of 209) with videos related to

Sort By:
Pageof 21
European Urology|January 18, 2006
The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomyFelix K-H Chun, Alberto Briganti, Thierry Lebeau, et al.
European Urology|October 30, 2007
Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliterSascha A Ahyai, Markus Graefen, Thomas Steuber, et al.
European Urology Focus|July 21, 2017
Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical PracticeMariana Reza, Mattias Ohlsson, Reza Kaboteh, et al.
The Journal of Urology|February 13, 2014
A tertiary Gleason pattern in the prostatectomy specimen and its association with adverse outcome after radical prostatectomyMeike Adam, Amir Hannah, Lars Budäus, et al.
Urology|August 12, 2008
Assessment of biochemical recurrence rate in patients with pathologically confirmed insignificant prostate cancerUmberto Capitanio, Sasha Ahyai, Markus Graefen, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 17, 2008
Clinical significance of p53 alterations in surgically treated prostate cancersThorsten Schlomm, Liv Iwers, Patrick Kirstein, et al.
Current Oncology (Toronto, Ont.)|April 21, 2022
Concordance between Preoperative mpMRI and Pathological Stage and Its Influence on Nerve-Sparing Surgery in Patients with High-Risk Prostate CancerClara Humke, Benedikt Hoeh, Felix Preisser, et al.
Urologic Oncology|May 4, 2019
Prostate cancer prognosis in men with other malignancies prior to radical prostatectomyPeter Klippenstein, Thorsten Schlomm, Gunhild von Amsberg, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|September 4, 2010
The novel nomogram of Gleason sum upgrade: possible application for the eligible criteria of low dose rate brachytherapyLars Budäus, Markus Graefen, Georg Salomon, et al.
European Urology|August 17, 2015
Nerve-sparing Surgery Technique, Not the Preservation of the Neurovascular Bundles, Leads to Improved Long-term Continence Rates After Radical ProstatectomyUwe Michl, Pierre Tennstedt, Lena Feldmeier, et al.
Pageof 21